Akebia Therapeutics Adds $16 Million
Akebia Therapeutics Inc., a Cincinnati-based developer of small-molecule drugs for anemia and vascular disorders, has raised $16 million in new Series A funding. The round total is now $25 million. Novartis Bioventures and Venture Investors co-led the extension, and were joined by return backers Triathlon Medical Ventures, Kearny Venture Partners, Athenian Venture Partners and Sigvion Capital.
29 July 2009•3 mins read
